For NCT02475213, patients with non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer and melanoma, were treated with enoblituzumab (investigational anti-B7H3 antibody), together with pembrolizumab, anti-PD1 inhibitor. This evidence concerns the gene CD276 and non-small cell lung carcinoma.